Context Therapeutics Inc is trading at $0.60 (8% down) as the stock extends its sharp decline following the release of interim Phase 1 data for its ovarian cancer candidate, CTIM-76.
- The sell-off began on June 15, 2026, when shares plummeted 51.14% as investors began reassessing the risk/reward profile of the CTIM-76 program.
- Today's downward movement appears to be follow-through selling from the initial data-driven catalyst rather than a response to a new development.
- The stock previously fell 4.24% on June 16, 2026, reflecting sustained bearish sentiment in the wake of the clinical update.